Fidelity Investments’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.28M | Buy |
267,188
+122,062
| +84% | +$536K | ﹤0.01% | 2907 |
|
|
2026
Q1 | $653K | Buy |
145,126
+8,570
| +6% | +$37.5K | ﹤0.01% | 3016 |
|
|
2025
Q4 | $657K | Buy |
136,556
+47,092
| +53% | +$212K | ﹤0.01% | 2983 |
|
|
2025
Q3 | $406K | Buy |
89,464
+8,723
| +11% | +$32K | ﹤0.01% | 3108 |
|
|
2025
Q2 | $249K | Buy |
80,741
+2,732
| +4% | +$9.07K | ﹤0.01% | 3228 |
|
|
2025
Q1 | $272K | Buy |
78,009
+101
| +0.1% | +$337 | ﹤0.01% | 3132 |
|
|
2024
Q4 | $255K | Sell |
77,908
-5,372
| -6% | -$19.8K | ﹤0.01% | 3173 |
|
|
2024
Q3 | $321K | Sell |
83,280
-17,538
| -17% | -$67.3K | ﹤0.01% | 3027 |
|
|
2024
Q2 | $312K | Sell |
100,818
-65,024
| -39% | -$195K | ﹤0.01% | 2888 |
|
|
2024
Q1 | $428K | Buy |
165,842
+498
| +0.3% | +$1.29K | ﹤0.01% | 2771 |
|
|
2023
Q4 | $413K | Sell |
165,344
-10,795
| -6% | -$21.1K | ﹤0.01% | 2734 |
|
|
2023
Q3 | $358K | Sell |
176,139
-8,766
| -5% | -$18.4K | ﹤0.01% | 2720 |
|
|
2023
Q2 | $425K | Sell |
184,905
-1,812
| -1% | -$4.72K | ﹤0.01% | 2708 |
|
|
2023
Q1 | $566K | Buy |
186,717
+1,509
| +0.8% | +$4.26K | ﹤0.01% | 2652 |
|
|
2022
Q4 | $432K | Sell |
185,208
-1,568
| -0.8% | -$3.75K | ﹤0.01% | 2761 |
|
|
2022
Q3 | $357K | Buy |
186,776
+23,469
| +14% | +$55.3K | ﹤0.01% | 2883 |
|
|
2022
Q2 | $443K | Sell |
163,307
-823
| -0.5% | -$2.11K | ﹤0.01% | 2885 |
|
|
2022
Q1 | $489K | Buy |
+164,130
| New | +$502K | ﹤0.01% | 2994 |
|
|
2021
Q3 | – | Sell |
-1
| Closed | – | – | 4258 |
|
|
2021
Q2 | $0 | Sell |
1
-299
| -100% | -$926 | ﹤0.01% | 4166 |
|
|
2021
Q1 | $1K | Buy |
+300
| New | +$1.16K | ﹤0.01% | 3787 |
|
|
2017
Q4 | – | Sell |
-19,200
| Closed | -$119K | – | 2647 |
|
|
2017
Q3 | $119K | Hold |
19,200
| – | – | ﹤0.01% | 2577 |
|
|
2017
Q2 | $69K | Hold |
19,200
| – | – | ﹤0.01% | 2605 |
|
|
2017
Q1 | $62K | Hold |
19,200
| – | – | ﹤0.01% | 2636 |
|
|
2016
Q4 | $47K | Hold |
19,200
| – | – | ﹤0.01% | 2640 |
|
|
2016
Q3 | $66K | Hold |
19,200
| – | – | ﹤0.01% | 2640 |
|
|
2016
Q2 | $67K | Hold |
19,200
| – | – | ﹤0.01% | 2637 |
|
|
2016
Q1 | $79K | Hold |
19,200
| – | – | ﹤0.01% | 2646 |
|
|
2015
Q4 | $85K | Buy |
19,200
+7,600
| +66% | +$41.7K | ﹤0.01% | 2712 |
|
|
2015
Q3 | $71K | Buy |
+11,600
| New | +$103K | ﹤0.01% | 2703 |
|
|
2015
Q2 | – | Sell |
-11,600
| Closed | -$203K | – | 2719 |
|
|
2015
Q1 | $203K | Buy |
+11,600
| New | +$238K | ﹤0.01% | 2718 |
|
Other funds holding ABUS
TSC
WCM
RCMNY
Fidelity Investments's ABUS Position: Q2 2026 in Review
Fidelity Investments increased its Arbutus Biopharma (ABUS) stake by 84% in Q2 2026, buying an estimated $536K and bringing the position to 267,188 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2907.
Fidelity Investments first reported a position in ABUS in Q1 2015 and has held it in 30 quarters since. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.
- Fidelity Investments held 267,188 shares of Arbutus Biopharma worth $1.28M as of Q2 2026.
- Fidelity Investments bought 122,062 Arbutus Biopharma shares in Q2 2026, an estimated $536K.
- Arbutus Biopharma made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #2907 holding.
- Fidelity Investments first reported a position in Arbutus Biopharma in Q1 2015 and has held it in 30 quarters since.
- 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.
Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.